Antimicrobial consumption in pediatric intensive care units during the first year of COVID-19 pandemic / Consumo antimicrobiano em unidades de cuidados intensivos pediátricos durante o primeiro ano da pandemia de COVID-19
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2021.10.11.21261865: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: Ethical approval: The study was submitted and approved by Ethics Committee of Faculty of Medicine (Universidade Federal Fluminense) and Prontobaby Group, under number 5.022.885 dated from October 6, 2021. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Software and Algorithms Sentences Resources Antibiotic policy restriction: The following antimicrobials were included in an antimicrobial restriction policy, requiring pre-approval by a paediatric infectious disease specialist: Amphotericin B lipid formulations, Caspofungin, Ceftazidime/Avibactam, Ceftobiprol, Colistin (inhaled), Daptomycin, Ertapenem, … SciScore for 10.1101/2021.10.11.21261865: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: Ethical approval: The study was submitted and approved by Ethics Committee of Faculty of Medicine (Universidade Federal Fluminense) and Prontobaby Group, under number 5.022.885 dated from October 6, 2021. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Software and Algorithms Sentences Resources Antibiotic policy restriction: The following antimicrobials were included in an antimicrobial restriction policy, requiring pre-approval by a paediatric infectious disease specialist: Amphotericin B lipid formulations, Caspofungin, Ceftazidime/Avibactam, Ceftobiprol, Colistin (inhaled), Daptomycin, Ertapenem, Imipenem, Linezolid, Meropenem, Micafungin, Polymyxin B, Teicoplanin, Tigecyclin, Voriconazole. Data source and statistical analysis: A descriptive analysis was performed using Microsoft Excel. Microsoft Excelsuggested: (Microsoft Excel, RRID:SCR_016137)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Consumption of Oseltamivir reached 43% of children admitted in 19 Brazilian PICUs with MIS-C. 6 In other countries as USA, where Remdesevir is available, similar percentage of antiviral use (46.2%) was reported in children admitted in PICU. 15 Limitation of this article includes that the findings reflect local reality of two major PICUs of Rio de Janeiro city. Another limitation was having carried out the study in hospitals with a well established ASP and stricted control of antimicrobials, which not to be the reality of many hospitals. We conclude that even during the first year of COVID pandemics, trends of antimicrobial consumption reduction were verified for antibiotics and antifungals in two PICUs and reduction for antiviral in one of them.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
